Stephens Investment Management Group LLC lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 9.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 587,929 shares of the life sciences company’s stock after acquiring an additional 50,003 shares during the quarter. Illumina accounts for approximately 1.7% of Stephens Investment Management Group LLC’s investment portfolio, making the stock its 3rd biggest holding. Stephens Investment Management Group LLC owned approximately 0.39% of Illumina worth $160,904,000 at the end of the most recent quarter.
Other institutional investors have also recently modified their holdings of the company. BlackRock Inc. acquired a new position in Illumina in the 2nd quarter worth about $3,374,423,000. Primecap Management Co. CA purchased a new position in Illumina during the second quarter worth approximately $617,981,000. Ninety One UK Ltd grew its holdings in Illumina by 37,920.0% in the third quarter. Ninety One UK Ltd now owns 1,359,974 shares of the life sciences company’s stock valued at $372,198,000 after purchasing an additional 1,356,397 shares during the period. Jupiter Topco LLC acquired a new stake in Illumina in the second quarter valued at approximately $358,652,000. Finally, Wellington Management Group LLP grew its holdings in Illumina by 190.1% in the second quarter. Wellington Management Group LLP now owns 1,812,928 shares of the life sciences company’s stock valued at $318,767,000 after purchasing an additional 1,188,004 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on the company. Jefferies Financial Group set a $235.00 target price on Illumina and gave the stock a “hold” rating in a research note on Monday. Wall Street Zen cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, November 7th. Zacks Research lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 1st. Canaccord Genuity Group upped their price objective on shares of Illumina from $205.00 to $300.00 and gave the stock a “hold” rating in a research report on Monday, October 19th. Finally, Barclays upped their price objective on shares of Illumina from $160.00 to $200.00 and gave the stock an “underweight” rating in a research report on Wednesday, October 7th. Nine analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, Illumina currently has a consensus rating of “Hold” and an average target price of $243.72.
Get Our Latest Stock Analysis on Illumina
Insiders Place Their Bets
In related news, Director Keith Meister sold 299,336 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the completion of the sale, the director owned 1,409,851 shares of the company’s stock, valued at approximately $307,291,123.96. This represents a 17.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 1,500,628 shares of company stock worth $335,394,565 in the last quarter. Insiders own 2.90% of the company’s stock.
Illumina Stock Up 3.7%
NASDAQ ILMN opened at $210.01 on Thursday. The business has a fifty day moving average price of $248.55 and a 200 day moving average price of $180.47. Illumina, Inc. has a one year low of $112.65 and a one year high of $309.35. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.05 and a current ratio of 2.63. The company has a market cap of $31.75 billion, a P/E ratio of 36.15, a P/E/G ratio of 2.75 and a beta of 1.46.
Illumina (NASDAQ:ILMN – Get Free Report) last announced its earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.26. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The company had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. During the same quarter in the previous year, the company posted $1.34 EPS. The firm’s quarterly revenue was up 4.2% on a year-over-year basis. Research analysts anticipate that Illumina, Inc. will post 5.43 EPS for the current fiscal year.
Illumina Company Profile
Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.
See Also
- Five stocks we like better than Illumina
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
